


AP 1614

IFW

61



Docket No. PG4733USw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Burbridge et al.
Serial No.: 10/018,640 Art Unit: 1614
Filing Date: March 20, 2002 Examiner: Kwon, Brian Yong S.
For: NEW USES FOR POTASSIUM CHANNEL OPENERS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- [X] Copies of the references are enclosed
[] Copies of the references were submitted in parent application Serial No. (37 CFR 1.98(d))
[] A copy of the International Search Report which issued on International Application No. is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. [] The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

[] The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. [X] The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.

CERTIFICATE OF MAILING (37 CFR 1.8)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date: May 6, 2004

Julie D. McFalls
Julie D. McFalls


Atty. Docket No. PG3733USw

- ☒ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- ☒ Please charge any required fees to Deposit Account No.07-1392.
- ☐ A duplicate copy of this paper is attached.

Respectfully Submitted,


Attorney of Record: Bonnie L. Deppenbrock
Registration No. 28,209

Date: May 6, 2004
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1577
Facsimile: (919) 483-7988



| | | | | | | | |
|---|----|--|-------------------------|---|------------------------|---------------------------------|-----------------------------------|
| FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT | | | | ATTORNEY DOCKET NO. PG3733USw | | SERIAL NO. 10/018,640 | |
| | | | | APPLICANT Burbridge et al. | | | |
| | | | | FILING DATE March 20, 2002 | | GROUP 1614 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| Examiner Initials | | Patent Number | Issue Date | Name | Class | Subclass | Filing Date If Appropriate |
| | 1 | 5,852,053 | 12/22/98 | Bartsch Reni et al. | | | |
| | 2 | 5,892,045 | 4/6/99 | Sit et al. | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Continue on page _____ | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | Document Number | Publication Date | Country | Class | Subclass | Translation Yes No |
| | 3 | 98/23273 | 6/4/98 | PCT | | | |
| | 4 | 98/04135 | 2/5/98 | PCT | | | |
| | 5 | 89/10757 | 11/16/89 | PCT | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Continue on page _____ | | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.) | | | | | | | |
| | 6 | Rundfelt, Chris et al., "Potassium Channels and Neurodegenerative Diseases", Drug News and Perspectives, Vol. 12, 2, pp. 99-104, March 1999. | | | | | |
| | 7 | Rostock et al., "Effects of the Anticonvulsant Retigabine in Neuropathic Pain Models in Rats", Naunyn-Schmiedeberg's Archives of Pharmacology, Springer, Berlin, DE, Vol. 361, no. 4, pp. 382, 2000. | | | | | |
| | 8 | Rundfelt, Chris et al., "The New Anticonvulsant Retigabine (D-23129) Acts as an opener of K ⁺ Channels in Neuronal Cells", European Journal of Pharmacology, Vol. 336, no. 2/3, pp. 243-249, October 8, 1997. | | | | | |
| | 9 | Scriabine, Alexander, "1998 annual Meeting of the Society for Neuroscience: New Drugs Affecting the Central Nervous System", CNS Drug Reviews, Vol. 4, no. 4, pp. 386-397, January 1998. | | | | | |
| | 10 | Buxton, A et al., "Cholinergic Agents and Delay-Dependent Performance in The Rat", Pharmacology Biochemistry and Behavior, Vol. 49, no. 4, pp. 1067-1073, December 1994. | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| Continue on page _____ | | | | | | | |
| EXAMINER | | | | | DATE CONSIDERED | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant. | | | | | | | |